# Spermatic Cord Paraganglioma With Histologically Malignant Features



Ah-Young Kwon, Haeyoun Kang, Hee Jung An, Gwangil Kim, Tae Hoen Kim, Jin-Hyung Heo, Hye Jin Lee, and Young Kwon Hong

Paragangliomas occur extremely rarely in the spermatic cord. A 40-year-old man presented with a scrotal mass that was diagnosed as spermatic cord paraganglioma with malignant histological features. To our knowledge, this is the first case of spermatic cord paraganglioma presented with malignant histological features evaluated by histological scoring. Careful evaluation of histological features and systematic evaluation should be considered for patients with spermatic cord paragangliomas. UROLOGY 93: e7–e8, 2016. © 2016 Elsevier Inc.

## **CASE PRESENTATION**

40-year-old man presented with a painless mass in the left scrotum with no accompanying symptoms. Genital sonography revealed a mass in the spermatic cord (Fig. 1A). The mass was removed with unilateral orchiectomy. (Fig. 1B). The pathological specimen was diagnosed as extra-adrenal paraganglioma with histological features of malignancy (Fig. 1C-F). Whole body positron emission tomography-computed tomography of the patient did not reveal other lesions. Spermatic cord paragangliomas are extremely rare, with only 9 cases reported in the literature to date.<sup>1-5</sup> Compared with previously reported cases (Supplementary Table S1), the present case showed histological features of malignancy (Pheochromocytoma of the Adrenal gland Scaled Score [PASS] 6) with moderate differentiation (Grading system for Adrenal Pheochromocytoma and Paraganglioma [GAPP] score 4) (Table 1). Currently, there are no standardized histological criteria. However, scoring systems such as PASS<sup>6</sup> and GAPP<sup>7</sup> have been proposed to provide clarification. To evaluate the histological features systematically, we used PASS and GAPP scores for the present case. To our knowledge, this is the first case of spermatic cord paraganglioma with histological features of malignancy classified using histological scoring. The clear identifier of malignant paraganglioma is the presence of metastasis. At 1-year follow-up, the patient showed no evidence of recurrence or metastasis. Therefore, we report this tumor as an extraadrenal paraganglioma with "histologically" malignant

Ah-Young Kwon and Haeyoun Kang contributed equally.

From the Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, South Korea; and the Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, South Korea

Address correspondence to: Young Kwon Hong, M.D., Ph.D., 59 Yatapro, Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, South Korea, 463-712. E-mail: urohong@cha.ac.kr

Submitted: December 11, 2015, accepted (with revisions): March 8, 2016



an ill-defined lobulated mass with heterogeneous echogenicity

in the left spermatic cord. (B) Gross features. A well-defined,

ovoid shaped, nonencapsulated, pale tan-colored firm mass mea-

suring  $1.8 \times 1.3$  cm with central hemorrhagic and ischemic ne-

crotic foci in the spermatic cord is shown (arrow). (C) Histologic

features. The tumor cells are arranged in well-defined nests ("Zellballen pattern") (H&E stain, 200×). (**D**) Immunohistochemical stain. The tumor cells showing positive reaction for synaptophysin (100×). The cells showing positive reactivity for

chromogranin (not shown); the sustentacular cells are posi-

tive for S-100 (not shown). (E) Perineural invasion. Perineural

Financial Disclosure: The authors declare that they have no relevant financial interests.

Table 1. PASS and GAPP score of the present c
---

	-		
Total score	6/20	Total score	4/10
hyperchromasia	0/ L		
Nuclear	0/1		
Protound nuclear	0/1		
Capsular invasion	0/1		
adipose tissue Vascular invasion	1/1		
Extension into	1/1		
Atypical mitotic	0/2	type	
0-1/10 HPF <sup>†</sup>	0/2	nonfunctioning	0/1
spindling	, 0,/0	3-5%	0./1
Tumor cell	2/2	Ki67 labeling index:	2/2
Cellular	2/2	Vascular or capsular	1/1
necrosis High cellularity	0/2	Comedo necrosis:	0/2
diffuse growth Central or	0/2	Zellballen Cellularity:	1/2
Large nests or	0/2	Histologic pattern:	0/2
PASS parameters*		GAPP parameters <sup>†</sup>	

GAPP, Grading system for Adrenal Pheochromocytoma and Paraganglioma; HPF, high-power field; PASS, Pheochromocytoma of the Adrenal gland Scoring Scale.

\*  $\geq$ 4, potentially malignant biological behavior; <4, benign biological behavior.

<sup>1</sup> 0-2: well-differentiated type; 3-6: moderately differentiated type; 7-10: poorly differentiated type.

×400.

features, avoiding the term "malignant" paraganglioma. We advise that patients should be carefully assessed when evaluating spermatic cord paragangliomas.

#### References

- Abe T, Matsuda H, Shindo J, Nonomura K, Koyanagi T. Ectopic pheochromocytoma arising in the spermatic cord 5 years after removal of bilateral carotid body tumors and adrenal pheochromocytomas. *Int J Urol.* 2000;7:110-111.
- Alataki D, Triantafyllidis A, Gaal J, et al. A non-catecholamineproducing sympathetic paraganglioma of the spermatic cord: the importance of performing candidate gene mutation analysis. *Virchows Arch.* 2010;457:619-622.
- 3. Attaran SY, Shakeri S, Sobhani AR. Paraganglioma of the spermatic cord: report of a case. J Urol. 1996;155:651.
- Bacchi CE, Schmidt RA, Brandao M, Scapulatempo R, Costa JC, Schmitt FC. Paraganglioma of the spermatic cord. Report of a case with immunohistochemical and ultrastructural studies. Arch Pathol Lab Med. 1990;114:899-901.
- Garaffa G, Muneer A, Freeman A, et al. Paraganglioma of the spermatic cord: case report and review of the literature. *ScientificWorldJournal*. 2008;8:1256-1258.
- Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. *Am J Surg Pathol.* 2002;26:551-566.
- Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. *Endocr Relat Cancer*. 2014;21:405-414.

### APPENDIX

#### SUPPLEMENTARY DATA

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.urology .2016.03.014.